BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 16936339)

  • 1. Improved survival of persons with human immunodeficiency virus type 1 infection in the era of highly active antiretroviral therapy in Taiwan.
    Hung CC; Hsiao CF; Chen MY; Hsieh SM; Chang SY; Sheng WH; Sun HY; Chang SC
    Jpn J Infect Dis; 2006 Aug; 59(4):222-8. PubMed ID: 16936339
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Delayed progression to death and to AIDS in a Hong Kong cohort of patients with advanced HIV type 1 disease during the era of highly active antiretroviral therapy.
    Wong KH; Chan KC; Lee SS
    Clin Infect Dis; 2004 Sep; 39(6):853-60. PubMed ID: 15472819
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk of recurrent nontyphoid Salmonella bacteremia in HIV-infected patients in the era of highly active antiretroviral therapy and an increasing trend of fluoroquinolone resistance.
    Hung CC; Hung MN; Hsueh PR; Chang SY; Chen MY; Hsieh SM; Sheng WH; Sun HY; Huang YT; Lo YC; Hsiao CF; Chang SC
    Clin Infect Dis; 2007 Sep; 45(5):e60-7. PubMed ID: 17682981
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Kaposi's sarcoma in patients with human immunodeficiency virus infection in Taiwan.
    Lin CY; Chen MY; Hsieh SM; Sheng WH; Sun HY; Lo YC; Hung CC; Chang SC
    J Microbiol Immunol Infect; 2009 Jun; 42(3):227-33. PubMed ID: 19812856
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Survival of HIV-infected injection drug users (IDUs) in the highly active antiretroviral therapy era, relative to sex- and age-specific survival of HIV-uninfected IDUs.
    Muga R; Langohr K; Tor J; Sanvisens A; Serra I; Rey-Joly C; Muñoz A
    Clin Infect Dis; 2007 Aug; 45(3):370-6. PubMed ID: 17599317
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term effectiveness of highly active antiretroviral therapy on the survival of children and adolescents with HIV infection: a 10-year follow-up study.
    Patel K; Hernán MA; Williams PL; Seeger JD; McIntosh K; Van Dyke RB; Seage GR;
    Clin Infect Dis; 2008 Feb; 46(4):507-15. PubMed ID: 18199042
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epidemiologic changes in bacteremic pneumococcal disease in patients with human immunodeficiency virus in the era of highly active antiretroviral therapy.
    Grau I; Pallares R; Tubau F; Schulze MH; Llopis F; Podzamczer D; Liñares J; Gudiol F;
    Arch Intern Med; 2005 Jul; 165(13):1533-40. PubMed ID: 16009870
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incidence and prognosis of CMV disease in HIV-infected patients before and after introduction of combination antiretroviral therapy.
    Salzberger B; Hartmann P; Hanses F; Uyanik B; Cornely OA; Wöhrmann A; Fätkenheuer G
    Infection; 2005 Oct; 33(5-6):345-9. PubMed ID: 16258865
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Ocular manifestations in patients with human immunodeficiency virus infection before and after the introduction of highly active antiretroviral therapy].
    Mesarić B; Lisić M; Kniewald T; Ugrinović N; Begovac J
    Lijec Vjesn; 2005; 127(5-6):123-8. PubMed ID: 16281473
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changes in the clinical spectrum of opportunistic illnesses in persons with HIV infection in Taiwan in the era of highly active antiretroviral therapy.
    Sun HY; Chen MY; Hsieh SM; Sheng WH; Chang SY; Hsiao CF; Hung CC; Chang SC
    Jpn J Infect Dis; 2006 Oct; 59(5):311-6. PubMed ID: 17060697
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of repeated cycles of structured therapy interruption on the rate of recovery of CD4+ T cells after highly active antiretroviral therapy resumption.
    León A; Martinez E; Milinkovic A; Mora B; Mallolas J; Blanco JL; Larrousse M; Laguno M; Gallart T; Plana M; Gatell JM; Garcia F
    J Antimicrob Chemother; 2009 Jan; 63(1):184-8. PubMed ID: 19001447
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Osteonecrosis in patients with human immunodeficiency virus type 1 infection in Taiwan.
    Ho YC; Shih TT; Lin YH; Hsiao CF; Chen MY; Hsieh SM; Sheng WH; Sun HY; Hung CC; Chang SC
    Jpn J Infect Dis; 2007 Nov; 60(6):382-6. PubMed ID: 18032839
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD4+ cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression.
    Moore RD; Keruly JC
    Clin Infect Dis; 2007 Feb; 44(3):441-6. PubMed ID: 17205456
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Non-Hodgkin's lymphoma in patients with human immunodeficiency virus infection in Taiwan.
    Yang CJ; Chen MY; Hsieh SM; Sheng WH; Sun HY; Hung CC; Chang SC
    J Microbiol Immunol Infect; 2010 Aug; 43(4):278-84. PubMed ID: 20688287
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Progression of HIV infection in the post-HAART era among a cohort of HIV+ Greek haemophilia patients.
    Katsarou O; Touloumi G; Antoniou A; Kouramba A; Hatzakis A; Karafoulidou A
    Haemophilia; 2005 Jul; 11(4):360-5. PubMed ID: 16011588
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Highly active antiretroviral therapy per se decreased mortality and morbidity of advanced human immunodeficiency virus disease in Hong Kong.
    Chan CW; Cheng LS; Chan WK; Wong KH
    Chin Med J (Engl); 2005 Aug; 118(16):1338-45. PubMed ID: 16157027
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of HAART therapy on co-infection of tuberculosis and HIV cases for 9 years in Taiwan.
    Tseng SH; Jiang DD; Hoi HS; Yang SL; Hwang KP
    Am J Trop Med Hyg; 2009 Apr; 80(4):675-7. PubMed ID: 19346398
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical impact of GB virus C viremia on patients with HIV type 1 infection in the era of highly active antiretroviral therapy.
    Sheng WH; Hung CC; Wu RJ; Wang JT; Chen PJ; Chang SC; Kao JH
    Clin Infect Dis; 2007 Feb; 44(4):584-90. PubMed ID: 17243064
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Postnatal HIV-1 transmission after cessation of infant extended antiretroviral prophylaxis and effect of maternal highly active antiretroviral therapy.
    Taha TE; Kumwenda J; Cole SR; Hoover DR; Kafulafula G; Fowler MG; Thigpen MC; Li Q; Kumwenda NI; Mofenson L
    J Infect Dis; 2009 Nov; 200(10):1490-7. PubMed ID: 19832114
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The cost-effectiveness of highly active antiretroviral therapy, Canada 1991-2001.
    Beck EJ; Mandalia S; Gaudreault M; Brewer C; Zowall H; Gilmore N; Klein MB; Lalonde R; Piché A; Hankins CA
    AIDS; 2004 Dec; 18(18):2411-8. PubMed ID: 15622317
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.